ERBB2 and ovarian cancer: Intratumoral injection of the HER2-CD3-Fc mRNA-LNPs triggers a strong antitumor response and completely blocks HER2-positive A1847 tumor growth without any signs of toxicity in an ovarian cancer xenograft model.